Oculis Holding AG (OCS) Income from Continuing Operations (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Income from Continuing Operations came in at 37094432.0 in Q1 2026, little changed year-on-year from 37264809.33 in Q1 2025, and down 151.01% quarter-over-quarter from 72715485.96 in Q4 2025.
Oculis Holding AG (OCS) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Oculis Holding AG's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 37094432.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations changed 0.46% year-over-year to 37094432.0 in Q1 2026; TTM through Mar 2026 was 21033180158.89, a 9.94% increase from a year earlier, with the FY2025 full-year figure at 119803537.24, down 22.42% from the prior year.
- Income from Continuing Operations declined to 37094432.0 in Q1 2026 per OCS's latest filing, from 72715485.96 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 72715485.96 in Q4 2025 and bottomed at 23261892784.97 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 21477057.43 (2023), against an average of 2783551865.92.
- Across the five-year window, Income from Continuing Operations slumped 116344.35% in 2024 and jumped 318.67% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 9561219.83 in 2022, then slumped by 47.68% to 14120114.78 in 2023, then tumbled by 135.51% to 33253672.96 in 2024, then soared by 318.67% to 72715485.96 in 2025, then slumped by 151.01% to 37094432.0 in 2026.
- Per Business Quant, the three latest OCS Income from Continuing Operations figures stand at 37094432.0 (Q1 2026), 72715485.96 (Q4 2025), and 21038093019.56 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.09 Mn |
| Dec 31, 2025 | 72.72 Mn |
| Sep 30, 2025 | -21.04 Bn |
| Jun 30, 2025 | -30.71 Mn |
| Mar 31, 2025 | -36.93 Mn |
| Dec 31, 2024 | -33.25 Mn |
| Sep 30, 2024 | -23.26 Bn |
| Jun 30, 2024 | -22.98 Mn |
| Mar 31, 2024 | -18.37 Mn |
| Dec 31, 2023 | -14.12 Mn |
| Sep 30, 2023 | -19.98 Mn |
| Jun 30, 2023 | -14.07 Mn |
| Mar 31, 2023 | -49.48 Mn |
| Dec 31, 2022 | -9.56 Mn |
| Sep 30, 2022 | -10.29 Mn |
| Jun 30, 2022 | -12.73 Mn |